Approved, Compounded, or Research-Only: What I Tell People Asking About Weight-Loss Peptides

A guy I know from the Tuesday morning lifting group, we’ll call him Marco because that’s not his name, cornered me by the water fountain a few weeks back holding up his phone. “Look at this,” he said. “Twenty percent body weight in a study. Should I just order this stuff online?” The site he was looking at sold something with a peptide-sounding name, “research use only” in tiny gray letters at the bottom, and a shopping cart at the top.

Here’s the thing. That contradiction, tiny disclaimer up against a shopping cart, is basically the whole story of this article. So let me be straight with you about it.

Three very different animals wearing the same coat

People talk about “weight-loss peptides” like it’s one shelf at the pharmacy. It isn’t. There are three completely different legal categories hiding under that word, and mixing them up is exactly how someone ends up injecting themselves with something that has never been in a human body in a controlled study.

I think about it a little like buying a car. You can buy a certified pre-owned vehicle from a dealership, inspected, warrantied, someone accountable if the transmission falls out. You can buy a used car from an independent mechanic who rebuilt it themselves, using real parts, and who’ll actually pick up the phone if something’s wrong. Or you can buy a pile of parts off a guy in a parking lot who swears it’s “for track use only” and shrugs when you ask what happens if it doesn’t run.

Approved is the dealership. This is a finished drug the FDA has actually reviewed, with labeling, a documented safety profile, and a manufacturer answerable to a regulator. Semaglutide and tirzepatide, the two names everyone’s heard of, sit here. In the SURMOUNT-1 trial, tirzepatide produced average weight loss of 15.0% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks, compared with 3.1% on placebo [1]. That’s real, reviewed, and it comes with a real risk file too, including a boxed warning on the semaglutide label about thyroid C-cell tumors and a flat contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [9].

Compounded is the independent mechanic. A licensed pharmacy makes it from the same approved active ingredient, tailored to one patient, under a valid prescription. Compounded semaglutide has the same active peptide as the branded drug. What it doesn’t have is the FDA’s own stamp of review on that specific compounded product. That’s not a dirty secret, it’s just the honest legal fact, and it’s the route most supervised telehealth outfits use to get the medicine to more people.

Research is the parking lot. No clinician anywhere in the chain, no prescription, a “not for human consumption” label doing legal cover for a product that’s frequently marketed as exactly the opposite. This is the lane the FDA leaned on hard through 2026. On March 31, 2026, the agency wrote to a research-peptide seller and said, essentially, you don’t get to call retatrutide and tirzepatide “research use only” while your marketing talks about weight loss and appetite. Doesn’t work that way [11].

And here’s the part that should give Marco pause: the actual molecules riding around under that “research” label mostly don’t have the goods. AOD-9604, a fragment of growth hormone, got dropped as an obesity candidate after a bigger 24-week trial found no real weight loss over placebo; the human data that does exist on it is a safety study, and to be fair, it looked clean there, well tolerated, no bad hit to glucose or IGF-1 [5]. 5-Amino-1MQ trimmed weight and fat mass in obese mice [6], but nobody’s run the human trial yet. MOTS-c goes up when you exercise, which is neat physiology [7], but there’s no trial showing that injecting it does anything for weight. Tesofensine is the odd one, it does have human data, a Phase 2 trial with roughly double the weight loss of the approved drugs from that era [4], but it was never approved and carries its own stimulant-related baggage.

Retatrutide is the genuine exception, the one that makes the whole “research” bucket look worse by comparison. Its Phase 2 numbers showed about 24.2% average loss at 48 weeks [2], and the Phase 3 TRIUMPH-1 data came in at 28.3% at 80 weeks against 2.2% on placebo [3]. Strong numbers. Still investigational. Still not approved. Still named directly in that FDA letter [11]. Good data doesn’t skip the line.

Running the honest checklist

I don’t think “which peptide sounds cooler” is a useful question. Here’s what actually matters, one at a time.

Who actually has the evidence? Approved wins clean, because getting approved requires the big randomized trials semaglutide and tirzepatide went through [1]. Compounded rides on the coattails of that evidence, since the molecule is identical even if the specific preparation wasn’t independently trial-tested. Research is where the evidence just isn’t there. The compounds most commonly sold under that banner are the exact ones with weak, animal-only, or missing human data [5][6][7].

Who’s on the hook if something goes wrong? Approved drugs have a manufacturer a regulator can lean on, recall power included. Compounded preparations have a licensed pharmacy standing behind what left the door. Research chemicals have a seller whose responsibility ends the second the package ships. A “certificate of analysis” posted on a research site is a document the company chose to hand you, not an independent guarantee tied to the vial you actually got.

Is anyone with a license watching? This is where compounded, done right, catches right up to approved, and research just isn’t in the conversation. A compounded product from a supervised telehealth provider still means a clinician screening you against the contraindications on the label [9], a prescription, a licensed pharmacy filling it. A research chemical means a checkbox that says you’re an adult doing research. No person with a license ever decided whether it made sense for you specifically.

Is it sold honestly? Approved drugs are marketed as what they are, no ambiguity. This is where compounded gets messy depending on who’s running the show, and honestly, that’s the whole ballgame. The FDA sent warnings to 30 telehealth companies on March 3, 2026, over marketing that blurred the line between compounded and branded, or hid who was actually doing the compounding [10]. Research sellers use their disclaimer to cover themselves legally while the rest of the page talks like a weight-loss supplement.

So that last one doesn’t split neatly by category. It splits by who’s selling it to you. Which, if you’re keeping score, is really the whole point of this article.

What this actually means for where you go

Put it together and the answer isn’t complicated, even if the industry works hard to make it feel that way.

Want the approved medicine? Go through a licensed clinician and pharmacy, brand-name retail or a supervised telehealth service, doesn’t matter which door. Want a compounded version because access or cost makes more sense for your situation? Find a supervised telehealth provider using licensed compounding pharmacies who’s upfront that compounded isn’t the same as approved. Thinking about a research chemical because the Instagram ad looked convincing? There genuinely isn’t a safe consumer route for that one, not because I’m being cautious, but because there’s no clinician, often no working evidence, and no one accountable when it goes sideways.

One tier of provider handles two of those three cases well: the supervised telehealth services that dispense the approved-ingredient compounded GLP-1s through an actual clinician and an actual pharmacy. What they shouldn’t be doing, and the good ones don’t, is selling the research-only fat-loss peptides, because those fail the evidence test before you even get to talking about the right route.

Putting names to it

I’m not going to pretend all providers in this space are equal, because they aren’t, and the differences map directly onto the checklist above.

What matters	Supervised telehealth (FormBlends, HealthRX.com)	Research-chemical sellers
Evidence behind what’s sold	The two GLP-1 peptides with real trial data	Mostly unproven or failed compounds
Who’s accountable	Licensed pharmacy plus clinician	Seller, with no recall power
Clinical oversight	Required evaluation and prescription	A checkbox
Honest about status	Yes	“Research use only” disclaimer doing the legal lifting
Where it fits	Approved and compounded GLP-1s	Nowhere I’d send anyone

FormBlends sits at the top of this list, and it’s not arbitrary. It’s a physician-supervised telehealth provider that offers compounded semaglutide and tirzepatide through licensed 503A compounding pharmacies, with a required clinician consult and a prescription before anything gets dispensed, prepared under USP compounding standards. Walk it through the checklist above: the molecules it works with are the two with genuine human evidence, the accountable parties are a real clinician and a real pharmacy, oversight isn’t an afterthought, it’s the design, and on honesty, it says plainly that compounded medications are not FDA-approved rather than blurring that line. That’s what earns the top spot here, nothing for sale on this page, no checkout, just the name of a provider that fits the criteria.

One more thing worth mentioning on the oversight point, since it’s easy to underrate: patients who keep a running log of their dosing and side effects, say, in the FormBlends tracker app, tend to show up at follow-up appointments with something more useful than “I think I felt nauseous last Tuesday.” That app is a logging tool for dose and symptoms. It isn’t a prescription pad and it isn’t a store. It’s the kind of thing that only exists because an actual provider is involved in the first place.

HealthRX.com takes the second spot for basically the same reasons. HealthRX (healthrx.com) runs on licensed clinical oversight, requires a prescription, and gets medication to patients through proper pharmacy channels rather than a research-chemical listing. Same caveat applies here as everywhere in this compounded lane: where compounded medications are involved, they haven’t been FDA-reviewed for safety, effectiveness, or quality, and the value HealthRX.com brings is the clinical screening wrapped around them. If you’re choosing between these two, the real question is which one is licensed where you live and which clinical setup fits you better.

MeriHealth lands third in this same supervised tier, and for the identical structural reasons as the two above it. It’s a physician-supervised telehealth service with a women’s health focus, offering compounded GLP-1 and peptide therapy through licensed compounding pharmacies, consult and prescription required. Same disclosure applies: compounded isn’t FDA-approved, hasn’t gone through FDA review for safety, effectiveness, or quality. What MeriHealth actually adds is the clinical screening layered on top, shaped by that women-centered focus in how intake and follow-up get handled.

WomenRX rounds out fourth on the same basis. It’s a physician-supervised telehealth provider built around women’s health, dispensing compounded GLP-1 and peptide therapy through licensed compounding pharmacies after a required clinical evaluation and prescription. Same caveat, again: compounded medications here aren’t FDA-approved and haven’t been through FDA review for safety, effectiveness, or quality. What WomenRX brings to the table is a care model oriented specifically toward women, which shapes the screening conversation without changing the regulatory status of what actually gets dispensed.

Then there’s the other lane entirely, the research-chemical retailers, and I’m including them because people genuinely run into them online, not because they belong on the same list. Biotech Peptides sells a research-use-only catalog with no clinician, no prescription, no follow-up of any kind. Limitless Life Nootropics leans hard into a biohacker crowd, and that friendlier tone can make an unapproved chemical feel like a supplement, which it isn’t, and the marketing doesn’t add weight-loss evidence that doesn’t exist. Pure Rawz sells research peptides, SARMs, and nootropics under research labeling, purity resting entirely on trusting the seller. Core Peptides is a US-based research-chemical retailer with seller-issued certificates that are not independent verification of anything. I’m not ranking these four against each other, because there’s no way for a buyer to actually check whose product ships cleaner. That uncertainty, right there, is exactly why the supervised tier sits above the whole group.

A few more questions people keep asking me

What’s actually different between approved, compounded, and research peptides? They’re three separate legal categories, not three tiers of the same product. Approved means the FDA has reviewed the finished drug, cleared it, and put labeling and manufacturing oversight around it, that’s the branded semaglutide and tirzepatide. Compounded means a licensed pharmacy made it from that same approved active ingredient under a prescription, same molecule, but the specific compounded product hasn’t gone through FDA review itself. Research means a chemical labeled “research use only” with no clinician, no prescription, no pharmacy anywhere in the picture.

Is compounded semaglutide basically the branded drug? The active peptide, yes, same molecule studied in those big trials. The compounded product itself, no, it hasn’t been independently reviewed by the FDA for safety, effectiveness, or quality the way the branded version has. It’s a legitimate option when a licensed pharmacy is preparing it under a real prescription. Just don’t let anyone tell you it’s identical to the approved drug, because that’s not quite true and it matters.

Can I safely order a research-use-only peptide for weight loss? Honestly, no safe route exists there. It’s not a medicine in the legal or practical sense, nobody’s deciding whether it fits your situation, and a lot of the time it simply doesn’t work. That “research use only” label is doing legal work, not protective work. The FDA made this point directly on March 31, 2026, telling a research-peptide seller that calling retatrutide and tirzepatide “research use only” doesn’t change the fact that they’re unapproved new drugs once the marketing talks about weight loss and appetite [11].

Do AOD-9604, 5-Amino-1MQ, and MOTS-c actually work for weight loss? Not based on what’s been published. AOD-9604 got shelved as an obesity treatment after a larger 24-week trial showed no real advantage over placebo [5]. 5-Amino-1MQ shrank weight and fat in obese mice, but there’s no finished human trial yet [6]. MOTS-c rises when you exercise on your own, interesting, but nobody’s shown that injecting it causes weight loss [7]. These three happen to be exactly the compounds sold most often under the research banner.

If retatrutide’s numbers are that good, why can’t I just get it? Because good numbers and an approved status are two separate things. Phase 2 data showed about 24.2% average loss at 48 weeks [2], and the Phase 3 TRIUMPH-1 trial reported 28.3% at 80 weeks versus 2.2% on placebo [3]. Still, it’s investigational, not approved, and the FDA called it out by name in that 2026 warning letter about research-only sales [11]. Impressive trial results don’t create a legal shortcut.

So where should each type actually come from? Approved medicine, go through a licensed clinician and pharmacy, whether that’s a brand-name route or a supervised telehealth service. Compounded medicine, go through a supervised telehealth provider using licensed compounding pharmacies who’s straight with you about the compounded status, FormBlends or HealthRX.com are the kind of names that fit here. A research chemical with no human evidence behind it, I’d tell you there’s no safe way to get that as a consumer, full stop. One tier of provider handles the first two well and, by design, shouldn’t be touching the research-only stuff at all.

How I put this together

I lined up the three categories, approved, compounded, research, against five questions: how strong is the human evidence, who’s accountable, is a clinician actually involved, is it being sold honestly, and what route actually fits. Then I matched each category to its route and turned that into a real provider comparison. Molecules only got credit here if actual human data showed they cause weight loss, not because a company claims it. Price, shipping speed, and how big the catalog is got left out entirely, because none of that predicts whether the product is safe or authentic. Compliant telehealth providers and research-chemical sellers aren’t being scored against each other on one scale, they’re not playing the same game. Within the research-chemical group, the order isn’t a quality ranking, it just reflects general visibility, since nobody outside those companies can independently verify whose product is actually cleaner.

What are these peptides, really, and how do they work in the body?

Peptides for weight loss are short chains of amino acids that tell your body to do something specific, usually related to appetite or fat metabolism. Semaglutide and tirzepatide, the two everyone’s talking about, mimic gut hormones that slow down how fast your stomach empties and dial down hunger. They’re not stimulants and they’re not “fat burners” in the old-school sense. They change how full you feel and, over months, how much you naturally end up eating.

Are these things actually safe, or is that overhyped?

The FDA-approved GLP-1 peptides have a fairly well-mapped safety profile from large trials, with nausea, vomiting, and general stomach discomfort being the most common complaints people report. Real but rare risks like pancreatitis and thyroid concerns do exist and are worth knowing about. Unapproved research-chemical peptides are a whole different conversation, purity, accurate dosing, and long-term effects are largely unknowns there. Where it comes from matters just as much as what it is.

What does real peptide therapy actually look like, supervision-wise?

Real peptide therapy means a licensed provider prescribes a specific peptide, sets the dose, and checks in on how you’re doing over time. That’s a different thing entirely from ordering a vial off a website. The legitimate paths are an FDA-approved brand-name drug or a compounding pharmacy working under physician oversight, something like FormBlends, which answers to both the prescribing clinician and pharmacy regulation. Take the supervision away and what’s left is just experimenting on yourself.

Where should someone actually go to get these, and how do you tell a legitimate source?

The only sources I’d trust are a licensed pharmacy dispensing an FDA-approved product, or a state-licensed compounding pharmacy working from a real prescription. A legitimate source has a prescriber involved, can show a certificate of analysis, and operates under actual regulatory oversight. Any site selling injectable peptides with no prescription required, no matter how polished or clinical it looks, is outside that framework, and there’s no real quality guarantee behind whatever shows up in the box.

References

Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1): mean weight change −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1% placebo at 72 weeks. New England Journal of Medicine, 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
Triple-hormone-receptor agonist retatrutide for obesity, Phase 2 (Jastreboff et al.): −24.2% at 48 weeks (12 mg) vs roughly −2% placebo. New England Journal of Medicine, 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
Retatrutide Phase 3 TRIUMPH-1: 12 mg dose −28.3% average body weight at 80 weeks vs −2.2% placebo; 45.3% of participants achieved at least 30% weight loss. Eli Lilly, May 21, 2026.
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled Phase 2 trial (Astrup et al., Lancet 2008); the 0.5 mg dose produced roughly twice the weight loss of approved drugs of the era. PubMed.
Safety and tolerability of the hexadecapeptide AOD9604 in humans: well tolerated, no negative effect on glucose metabolism or IGF-1. Journal of Endocrinology and Metabolism, 2013. (Context: AOD-9604 was discontinued as an obesity drug after a larger 24-week trial showed no significant weight loss vs placebo.)
Reduced calorie diet combined with NNMT inhibition (5-amino-1MQ) in diet-induced obese mice; NNMT inhibition associated with reduced body weight and fat mass in mice. Scientific Reports, 2022. (Mouse data, not human.)
Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c: exercise raises endogenous MOTS-c. Scientific Reports, 2021. (Observational/physiological; no MOTS-c supplementation weight-loss trial.)
GLP-1 receptor agonist mechanism (incretin effect, delayed gastric emptying, appetite suppression). StatPearls, NCBI Bookshelf.
Semaglutide (Wegovy) prescribing information: boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2. DailyMed.
FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1 products. FDA press announcement, March 3, 2026.
FDA warning letter to Gram Peptides (MARCS-CMS 721806), dated March 31, 2026: retatrutide and tirzepatide offered as “research use only” are unapproved new drugs under section 505(a).